VYNE THERAPEUTICS INC (VYNE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$39.50+8.46%
Close 2026-08-24 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
VYNE aims to grow revenue to about $39.6 million by mid-2025. The company is working to fix its business after losses. It has no recent market stress and some positive earnings beats. If it succeeds, it could become profitable.
VYNE is still losing money with negative EPS expected next years. It faces Nasdaq delisting risks and legal issues. Revenue is very low and uncertain. The turnaround may fail and losses could continue.
The market has no clear consensus or price targets. Estimates show continued losses. Our view is cautious given the lack of revenue growth and ongoing losses.
Breaks if: receives new delisting notice or fails to meet Nasdaq rules
Breaks if: EPS worsens beyond -$1.5 in 2026
revenue falls below $30 million by June 2025
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity, as VYNE is focused on advancing its clinical programs while managing financial challenges. The current thesis state is intact, supported by recent performance, but remains sensitive to market conditions and execution risks.
The market appears to have priced in a fragile valuation, reflecting the company's loss-making status and elevated risks. There is a premium compared to peers, indicating that investors expect some optionality in VYNE's future developments.
Fundamentals are likely to remain mixed as management works on advancing clinical trials and extending the cash runway. Recent financial performance has been neutral, but the risk of missing estimates is elevated due to the company's smaller size and the high miss-rate in the industry.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
The long-term thesis hinges on management's ability to execute on clinical development plans and maintain financial stability. Key factors include the performance of sector bellwethers and the potential impact of economic conditions on VYNE's operations.
In the next 1 to 3 years, VYNE's trajectory will depend on clinical advancements and market dynamics. Not investment advice.